RT Journal Article
SR Electronic
T1 Intrahepatic transcriptomics differentiate advanced fibrosis and clinical outcomes in adults with the Fontan circulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.05.23290997
DO 10.1101/2023.06.05.23290997
A1 Bravo-Jaimes, Katia
A1 Wu, Xiuju
A1 Reardon, Leigh C
A1 Lluri, Gentian
A1 Lin, Jeannette P
A1 Moore, Jeremy P
A1 Arsdell, Glen Van
A1 Biniwale, Reshma
A1 Si, Ming-Sing
A1 Naini, Bita V
A1 Venick, Robert
A1 Saab, Sammy
A1 Wray, Christopher L
A1 Ponder, Reid
A1 Rosenthal, Carl
A1 Klomhaus, Alexandra
A1 Böstrom, Kristina I
A1 Aboulhosn, Jamil A
A1 Kaldas, Fady M
YR 2023
UL http://medrxiv.org/content/early/2023/06/07/2023.06.05.23290997.abstract
AB Background The molecular mechanisms underlying Fontan associated liver disease (FALD) remain largely unknown. We aimed to assess intrahepatic transcriptomic differences among patients with FALD according to the degree of liver fibrosis and clinical outcomes.Methods This retrospective cohort study included adults with the Fontan circulation at the Ahmanson/UCLA Adult Congenital Heart Disease Center. Clinical, laboratory, imaging and hemodynamic data prior to the liver biopsy were extracted from medical records. Patients were classified into early (F1-F2) or advanced fibrosis (F3-F4). RNA was isolated from formalin-fixed paraffin embedded liver biopsy samples; RNA libraries were constructed using rRNA depletion method and sequencing was performed on Illumina Novaseq 6000. Differential gene expression and gene ontology analyses were carried out using DESeq2 and Metascape. Medical records were comprehensively reviewed for a composite clinical outcome which included decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, protein-losing enteropathy, chronic kidney disease stage 4 or higher, or death.Results Patients with advanced fibrosis had higher serum BNP levels and Fontan, mean pulmonary artery and capillary wedge pressures. The composite clinical outcome was present in 23 patients (22%) and was predicted by age at Fontan, right ventricular morphology and presence of aortopulmonary collaterals on multivariable analysis. Samples with advanced fibrosis had 228 up-regulated genes compared to early fibrosis. Samples with the composite clinical outcome had 894 up-regulated genes compared to those without it. A total of 136 up-regulated genes were identified in both comparisons and these genes were enriched in cellular response to cytokine stimulus, response to oxidative stress, VEGFA-VEGFR2 signaling pathway, TGF-beta signaling pathway, and vasculature development.Conclusions Patients with FALD and advanced liver fibrosis or the composite clinical outcome exhibit up-regulated genes including pathways related to inflammation, congestion, and angiogenesis. This adds further insight into FALD pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAdult Congenital Heart Association Research Grant 2021 (K.B.J.), NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881 (A.K.), NIH/NHLBI Grant Number HL81397 (K.I.B.), NIH/NHLBI Grant Number HL154548 (K.I.B.). Streisand/American Heart Association Endowed Chair in Cardiology (J.A.H.). Kelly Lee Tarantello Endowed Chair in Integrative Liver Transplantation (F.M.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLA IRB approved this project under number 21-001117I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe data can be accessed upon reasonable request.